No Data
InventisBio Gets Regulatory Approval to Market Gesorexel Tablets
Yifang Biotechnology (688382.SH): Type 1 innovative drug Gexolezepam tablet approved for market launch.
Yifang Biological (688382.SH) issued an announcement that the company and Zhengda Tianqing Pharmaceutical Group Co., Ltd. (referred to as "...
Yifang Biological-U (688382): Steadily advancing clinical progress, D-1553 approved for imminent listing.
Event: The company released the third quarter report of 2024, achieving revenue of 0.019 billion yuan in the first three quarters, a year-on-year decrease of 84.94%; net profit attributable to the parent company was -0.305 billion yuan; non-net profit attributable to the parent company was -0.313 billion yuan;经
bocom intl: sino biopharm's 3Q24 performance exceeded expectations, acquiring the controlling rights of the first A-share company.
Bocom Intl released a research report stating that Sino Biopharm (01177) had a 14.3% year-on-year increase in revenue to 5.47 billion yuan, with adjusted net income increasing by 58.0% to 0.6 billion yuan, both exceeding the bank's expectations. Management maintains a double-digit revenue growth guidance for the full year. In addition, the company acquired control of Haobobo (688656.SH) entering the immunodiagnostics track with an acquisition price of 33.74 yuan/share. After completion, Haobobo will become the first subsidiary of Sino Biopharm listed on the A-share market, with the bank believing its product portfolio will complement the company's respiratory, autoimmune, and other disease areas.
Yifang Biotech Report for the Third Quarter of 2024
Yifang Biotechnology (688382.SH): The net loss in the first three quarters was 0.305 billion yuan.
October 29th, Yifang Biology (688382.SH) released its third quarter report, with revenue of 19.156 million yuan in the first three quarters, a year-on-year decrease of 84.94%. The net loss was 0.305 billion yuan, and the non-net loss was 0.313 billion yuan, with a basic earnings per share of -0.53 yuan.
No Data
No Data